MiNK Therapeutics, Inc. (INKT) is a clinical-stage biopharmaceutical company developing allogeneic, "off-the-shelf" invariant natural killer T (iNKT) cell therapies. It is a common stock, not an ETF, and analyst coverage is thin. Two current, attributable price targets were reviewed. H.C. Wainwright analyst Emily Bodnar reiterated a Buy rating with a $35 target in May 2026. B. Riley Securities analyst Mayank Mamtani reiterated a Buy rating and raised the target to $50 from $43 on October 21, 2026.
The average analyst price target is therefore $42.50, the mean of $35 and $50. Both firms are bullish, but the $15 gap between them reflects genuinely different views on how quickly agenT-797 can advance and how the company will fund itself. No firm currently publishes a Sell or underweight rating with a target, though some third-party trackers list a legacy Hold view. Because only two targets exist, the $42.50 figure should be read as a thin, high-uncertainty estimate rather than a broad consensus.
INKT last traded near $10.63, giving the stock a market capitalization of roughly $54 million. From that level, the $42.50 central target implies approximately 300% upside, which is a very large move. The stock's 52-week range of $8.48 to $16.93 underscores how far the target sits above even the recent high.
The path toward $42.50 would almost certainly depend on transformative clinical news, not gradual re-rating. MiNK has no product revenue; trailing twelve-month EPS (earnings per share) is about -$2.39, and the company reported roughly $8.8 million in cash. A move of this magnitude would likely require positive data from agenT-797 in solid tumors or acute respiratory distress syndrome (ARDS), a new partnership, or a financing event that removes overhang concerns.
The 52-week high of $16.93 stands as the nearest major resistance level, well below the $42.50 target, while $8.48 marks the 52-week low and a key support level. The 50-day moving average near $11.43 and the 200-day average near $11.33 sit just above the current price, reinforcing that INKT trades in the middle of a multi-month range rather than in an established uptrend. Reaching $42.50 would require a sustained breakout far beyond any level the stock has traded in the past year.
Analyst price targets generally reflect a research horizon of roughly 12 months, though neither firm has publicly specified an exact timeline. Investors should monitor the next quarterly report expected in November 2026, clinical data readouts from agenT-797, any new collaboration or licensing announcements, and signs of additional capital raises. Changes in analyst targets or ratings are also worth watching given how few firms cover the stock.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on shifting market conditions, technical behavior, and AI-driven analysis. For a low-coverage, high-volatility name like INKT, these signals can help traders spot changing trends and manage positions more efficiently than manual chart review. Traders can use the tool to discover opportunities, monitor holdings, and react to momentum shifts as they develop.
The $42.50 stock price target is the average of two bullish analyst targets ($35 and $50) and implies roughly 300% upside from the recent price near $10.63. That is a very large move, achievable in practice only through major clinical or strategic developments for agenT-797. The pipeline and recent analyst upgrades provide genuine support for the long-term thesis, but financing risk, no current revenue, and the binary nature of clinical trials are substantial obstacles. With such thin coverage, the target carries unusually wide uncertainty, and investors should focus on upcoming data readouts and capital announcements rather than the target itself.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, INKT has been closely correlated with REVB. These tickers have moved in lockstep 66% of the time. This A.I.-generated data suggests there is a high statistical probability that if INKT jumps, then REVB could also see price increases.
| Ticker / NAME | Correlation To INKT | 1D Price Change % | ||
|---|---|---|---|---|
| INKT | 100% | -1.38% | ||
| REVB - INKT | 66% Closely correlated | -3.07% | ||
| KAPA - INKT | 50% Loosely correlated | -6.14% | ||
| RAIN - INKT | 43% Loosely correlated | -9.59% | ||
| CYPH - INKT | 42% Loosely correlated | -9.75% | ||
| PTHS - INKT | 41% Loosely correlated | -5.02% | ||
More | ||||